Results 181 to 190 of about 46,511 (209)

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Lancet, The, 2010
Joseph J Eron, Benjamin Young, Michael D Miller   +2 more
exaly  

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

New England Journal of Medicine, 2020
Yaseen M Arabi, Abdullah M Assiri, Hanan H Balkhy   +2 more
exaly  

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

Lancet, The, 2007
Kiat Ruxrungtham
exaly  

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Lancet, The, 2006
Vicente Estrada, Benjamin Young, Mark S Shaefer   +2 more
exaly  

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Lancet, The, 2008
jean-michel Molina, Ploenchan Chetchotisak   +1 more
exaly  

Lopinavir

2007
openaire   +1 more source

Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial

Lancet, The, 2016
Roselyne Vallo, Grace Ndeezi, Debra Jackson   +2 more
exaly  

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial

Med, 2020
Zhiwei Xie, Weiyin Lin, Weiping Cai
exaly  

Lopinavir

2017
openaire   +1 more source

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

New England Journal of Medicine, 2002
Jose Arribas
exaly